Mitochondrial dysfunction is not defined as an isolated “ATP problem” in the Hallmarks of Ageing framework, but as a systemic shift in bioenergetics, redox signaling, quality control and immune metabolism. In the Hallmark update (2023), the mitochondrial axis remains central and explicitly interacts with “disabled macroautophagy”, chronic inflammation and other Hallmarks. For medical practice, this entails a double task: to understand the mechanisms scientifically correctly (including their adaptivity and tissue specificity) and to keep the clinical translation evidence-based – especially where mitochondria-targeted interventions are increasingly marketed as “longevity”, but the data situation is still endpoint- and population-dependent.
Autoren
- Tanja Schliebe
Publikation
- Longevity-Special
You May Also Like
- Lung cancer
Multidisciplinary teams in oncology
- Adrenogenital syndrome
Clinical care from birth to adulthood
- Psoriasis: System therapies in everyday practice
Current real-world data at a glance
- Omega-3 fatty acids for obesity and type 2 diabetes
More fish oil for better lipid and HbA1c levels
- MASLD often goes unnoticed and is underestimated
Think tank for improving the supply situation
- DGPPN Congress
People at the center of care
- Diagnostics of respiratory viral infections
What is tested when and on whom?
- Lung cancer